Literature DB >> 26839314

Ubiquitin-specific Protease 20 Regulates the Reciprocal Functions of β-Arrestin2 in Toll-like Receptor 4-promoted Nuclear Factor κB (NFκB) Activation.

Pierre-Yves Jean-Charles1, Lisheng Zhang1, Jiao-Hui Wu1, Sang-Oh Han1, Leigh Brian1, Neil J Freedman2, Sudha K Shenoy3.   

Abstract

Toll-like receptor 4 (TLR4) promotes vascular inflammatory disorders such as neointimal hyperplasia and atherosclerosis. TLR4 triggers NFκB signaling through the ubiquitin ligase TRAF6 (tumor necrosis factor receptor-associated factor 6). TRAF6 activity can be impeded by deubiquitinating enzymes like ubiquitin-specific protease 20 (USP20), which can reverse TRAF6 autoubiquitination, and by association with the multifunctional adaptor protein β-arrestin2. Although β-arrestin2 effects on TRAF6 suggest an anti-inflammatory role, physiologic β-arrestin2 promotes inflammation in atherosclerosis and neointimal hyperplasia. We hypothesized that anti- and proinflammatory dimensions of β-arrestin2 activity could be dictated by β-arrestin2's ubiquitination status, which has been linked with its ability to scaffold and localize activated ERK1/2 to signalosomes. With purified proteins and in intact cells, our protein interaction studies showed that TRAF6/USP20 association and subsequent USP20-mediated TRAF6 deubiquitination were β-arrestin2-dependent. Generation of transgenic mice with smooth muscle cell-specific expression of either USP20 or its catalytically inactive mutant revealed anti-inflammatory effects of USP20in vivoandin vitro Carotid endothelial denudation showed that antagonizing smooth muscle cell USP20 activity increased NFκB activation and neointimal hyperplasia. We found that β-arrestin2 ubiquitination was promoted by TLR4 and reversed by USP20. The association of USP20 with β-arrestin2 was augmented when β-arrestin2 ubiquitination was prevented and reduced when β-arrestin2 ubiquitination was rendered constitutive. Constitutive β-arrestin2 ubiquitination also augmented NFκB activation. We infer that pro- and anti-inflammatory activities of β-arrestin2 are determined by β-arrestin2 ubiquitination and that changes in USP20 expression and/or activity can therefore regulate inflammatory responses, at least in part, by defining the ubiquitination status of β-arrestin2.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  NFκB; TNF receptor-associated factor (TRAF); Toll-like receptor 4 (TLR4); USP20; deubiquitylation (deubiquitination); inflammation; neointimal hyperplasia; scaffold; ubiquitin; β-arrestin

Mesh:

Substances:

Year:  2016        PMID: 26839314      PMCID: PMC4817176          DOI: 10.1074/jbc.M115.687129

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

Review 1.  Arrestins come of age: a personal historical perspective.

Authors:  Robert J Lefkowitz
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 2.  Arrestins as regulators of kinases and phosphatases.

Authors:  Louis M Luttrell; William E Miller
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

3.  Distinct roles for β-arrestin2 and arrestin-domain-containing proteins in β2 adrenergic receptor trafficking.

Authors:  Sang-Oh Han; Reddy P Kommaddi; Sudha K Shenoy
Journal:  EMBO Rep       Date:  2012-12-04       Impact factor: 8.807

Review 4.  TGFβ signalling in context.

Authors:  Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09-20       Impact factor: 94.444

5.  Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice.

Authors:  Wei Jin; Mikyoung Chang; Emmanuel M Paul; Geetha Babu; Andrew J Lee; William Reiley; Ato Wright; Minying Zhang; Jun You; Shao-Cong Sun
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

6.  The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-kappaB target genes.

Authors:  Susanne Wolfrum; Daniel Teupser; Marietta Tan; Kwan Y Chen; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-15       Impact factor: 11.205

Review 7.  Protein partners of deubiquitinating enzymes.

Authors:  Karen H Ventii; Keith D Wilkinson
Journal:  Biochem J       Date:  2008-09-01       Impact factor: 3.857

8.  Ubiquitination of beta-arrestin links seven-transmembrane receptor endocytosis and ERK activation.

Authors:  Sudha K Shenoy; Larry S Barak; Kunhong Xiao; Seungkirl Ahn; Magali Berthouze; Arun K Shukla; Louis M Luttrell; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2007-07-31       Impact factor: 5.157

9.  Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration.

Authors:  Jihee Kim; Lisheng Zhang; Karsten Peppel; Jiao-Hui Wu; David A Zidar; Leigh Brian; Scott M DeWire; Sabrina T Exum; Robert J Lefkowitz; Neil J Freedman
Journal:  Circ Res       Date:  2008-06-02       Impact factor: 17.367

10.  MARCH2 promotes endocytosis and lysosomal sorting of carvedilol-bound β(2)-adrenergic receptors.

Authors:  Sang-oh Han; Kunhong Xiao; Jihee Kim; Jiao-Hui Wu; James W Wisler; Nobuhiro Nakamura; Neil J Freedman; Sudha K Shenoy
Journal:  J Cell Biol       Date:  2012-11-19       Impact factor: 10.539

View more
  16 in total

1.  The deubiquitinase ubiquitin-specific protease 20 is a positive modulator of myocardial β1-adrenergic receptor expression and signaling.

Authors:  Samuel Mon-Wei Yu; Pierre-Yves Jean-Charles; Dennis M Abraham; Suneet Kaur; Clarice Gareri; Lan Mao; Howard A Rockman; Sudha K Shenoy
Journal:  J Biol Chem       Date:  2018-12-11       Impact factor: 5.157

Review 2.  Regulation of inflammation by β-arrestins: Not just receptor tales.

Authors:  Neil J Freedman; Sudha K Shenoy
Journal:  Cell Signal       Date:  2017-02-09       Impact factor: 4.315

Review 3.  Coupling Conjugation and Deconjugation Activities to Achieve Cellular Ubiquitin Dynamics.

Authors:  Casey P Nielsen; Jason A MacGurn
Journal:  Trends Biochem Sci       Date:  2020-02-28       Impact factor: 13.807

Review 4.  G Protein-Coupled Receptor Signaling Through β-Arrestin-Dependent Mechanisms.

Authors:  Pierre-Yves Jean-Charles; Suneet Kaur; Sudha K Shenoy
Journal:  J Cardiovasc Pharmacol       Date:  2017-09       Impact factor: 3.105

5.  Surfactant Protein A Enhances the Degradation of LPS-Induced TLR4 in Primary Alveolar Macrophages Involving Rab7, β-arrestin2, and mTORC1.

Authors:  Katja Freundt; Christian Herzmann; Dominika Biedziak; Claudia Scheffzük; Karoline I Gaede; Cordula Stamme
Journal:  Infect Immun       Date:  2021-11-15       Impact factor: 3.609

6.  USP20 (Ubiquitin-Specific Protease 20) Inhibits TNF (Tumor Necrosis Factor)-Triggered Smooth Muscle Cell Inflammation and Attenuates Atherosclerosis.

Authors:  Pierre-Yves Jean-Charles; Jiao-Hui Wu; Lisheng Zhang; Suneet Kaur; Igor Nepliouev; Jonathan A Stiber; Leigh Brian; Rui Qi; Virginia Wertman; Sudha K Shenoy; Neil J Freedman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

7.  The deubiquitinating enzyme USP20 stabilizes ULK1 and promotes autophagy initiation.

Authors:  Jun Hwan Kim; Dongyeob Seo; Sun-Jick Kim; Dong Wook Choi; Jin Seok Park; Jihoon Ha; Jungwon Choi; Ji-Hyung Lee; Su Myung Jung; Kyoung-Wan Seo; Eun-Woo Lee; Youn Sook Lee; Heesun Cheong; Cheol Yong Choi; Seok Hee Park
Journal:  EMBO Rep       Date:  2018-02-27       Impact factor: 8.807

8.  TRAF molecules in inflammation and inflammatory diseases.

Authors:  Almin I Lalani; Sining Zhu; Samantha Gokhale; Juan Jin; Ping Xie
Journal:  Curr Pharmacol Rep       Date:  2017-12-20

9.  Interleukin-9 mediates chronic kidney disease-dependent vein graft disease: a role for mast cells.

Authors:  Lisheng Zhang; Jiao-Hui Wu; James C Otto; Susan B Gurley; Elizabeth R Hauser; Sudha K Shenoy; Karim Nagi; Leigh Brian; Virginia Wertman; Natalie Mattocks; Jeffrey H Lawson; Neil J Freedman
Journal:  Cardiovasc Res       Date:  2017-11-01       Impact factor: 10.787

Review 10.  Deubiquitinases: Novel Therapeutic Targets in Immune Surveillance?

Authors:  Gloria Lopez-Castejon; Mariola J Edelmann
Journal:  Mediators Inflamm       Date:  2016-08-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.